News | November 01, 2023
Pfizer posts Q3 loss as Covid-19 revenues shrink
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
Merck continues progress in helping to protect people at risk of Zaire ebolavirus disease
Bayer reported the highest market capitalization growth of 23.1% during Q1 2023
he product will be launched shortly in the US market.
FDA also accepts a separate supplemental application to extend prophylaxis with PREVYMIS to 200 days in certain HSCT recipients
OmiCrisp has been developed with support from Centre for Cellular And Molecular Platforms C-CAMP-InDx Program
WHO made a strong recommendation for nirmatrelvir and ritonavir for mild and moderate COVID-19 patients at highest risk of hospital admission
Separate Phase 3 study evaluating 200 days of therapy with PREVYMIS in HSCT recipients at high risk of late clinically significant CMV infection recently completed, meeting its primary endpoint
The Coalition for Epidemic Preparedness Innovations (CEPI) has recently partnered with the consortium of India-based Bharat Biotech, University of Sydney and ExcellGene to develop “variantproof” COVID-19 vaccine.
Japan’s Ministry of Health, Labour and Welfare (MHLW) has recently approved AstraZeneca's long-acting antibody combination “Evusheld” for the prevention ) and treatment of COVID-19.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
